1 citations · 1 across the 3 of their papers we have counts for
6 papers
Backfilling Cohorts in Phase I Dose-Escalation Studies
Helen Barnett, Oliver Boix, Dimitris Kontos +1
The use of `backfilling', assigning additional patients to doses deemed safe, in phase I dose-escalation studies has been used in practice to collect additional information on the…
Dose Finding Studies for Therapies with Late-Onset Safety and Efficacy Outcomes
Helen Barnett, Oliver Boix, Dimitris Kontos +1
In Phase I/II dose-finding trials, the objective is to find the Optimal Biological Dose (OBD), a dose that is both safe and efficacious that maximises some optimality criterion bas…
Dose Finding Studies for Therapies with Late-Onset Toxicities: A Comparison Study of Designs
Helen Barnett, Oliver Boix, Dimintris Kontos +1
An objective of phase I dose-finding trials is to find the maximum tolerated dose; the dose with a particular risk of toxicity. Frequently, this risk is assessed across the first c…
A Comparison of Model-Free Phase I Dose Escalation Designs for Dual-Agent Combination Therapies
Helen Yvette Barnett, Matthew George, Donia Skanji +3
It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the ri…
A Novel Statistical Test for Treatment Differences in Clinical Trials using a Response Adaptive Forward Looking Gittins Index Rule
Helen Yvette Barnett, Sofia S Villar, Helena Geys +1
The most common objective for response adaptive clinical trials is to seek to ensure that patients within a trial have a high chance of receiving the best treatment available by al…
A Seamless Phase I/II Platform Design with a Time-To-Event Efficacy Endpoint for Potential COVID-19 Therapies
Thomas Jaki, Helen Barnett, Andrew Titman +1
In the search for effective treatments for COVID-19, initial emphasis has been on re-purposed treatments. To maximise the chances of finding successful treatments, novel treatments…